Overview
Jarom Kesler is a partner in our Orange County office.
He provides guidance on strategic patent portfolio and trade secret management, analysis of infringement and invalidity issues, due diligence, and intellectual property licensing matters. Mr. Kesler’s particular expertise lies in the area of portfolio management in view of contentious proceedings. He procures patents in anticipation of and during the course of litigation, and has successfully represented clients involved in inter partes review, interference and reexamination matters before the U.S. Patent and Trademark Office (USPTO) and Federal Circuit.
Mr. Kesler’s practice focuses on the medical device, electronics, signal processing, software and information technology areas. He represents a variety of large and small companies in technologies that integrate hardware and software including such areas as non-invasive medical diagnostics, internet gateway and packet routing technology, performance diagnostics and green energy technology.
Mr. Kesler joined the firm in 2005 and became a partner in 2011.
Education
- University of Minnesota Law School (J.D., 2005), cum laude, Director - University of Minnesota Intellectual Property Moot Court
- Brigham Young University (B.S. Electrical Engineering, 2002)
Recognition
Awards & Honors
-
Named to IAM Strategy 300: The World’s Leading IP Strategists (2023-2024) which “identifies the individuals who are leading the way in the development and implementation of strategies that maximize the value of IP portfolios”
- Recognized in Patexia’s 2023 PTAB Intelligence Report as a “Top Performer” based on activity and performance before the PTAB
News & Insights
Articles
“Barriers to Entry: The Patent System’s Silver Bullet for Medical Companies,” Diagnostics World News (May 2019)
“Intellectual Property Can Make or Break the Best Ideas,” RTC Magazine (March 2016)
“What Medical Device Companies Need to Know about Intellectual Property”, Medical Electronic Device Solutions (MEDS) Magazine (August 2012)
New Patent Rules Will Affect Your Company’s Patent Strategy, September 20, 2007